Active, not recruitingPhase 2NCT03731260
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
Studying Indolent systemic mastocytosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Blueprint Medicines Corporation
- Intervention
- Avapritinib(drug)
- Enrollment
- 251 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2027
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Mayo Clinic Hospital, Phoenix, Arizona, United States
- Stanford Cancer Institute, Stanford, California, United States
- Mayo Clinic Florida, Jacksonville, Florida, United States
- H. Lee Moffitt Cancer Center, Tampa, Florida, United States
- Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
- Rush University Medical Center, Chicago, Illinois, United States
- University of Kansas Hospital, Kansas City, Kansas, United States
- Brigham & Women's Hospital, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Michigan Medicine, University of Michigan, Ann Arbor, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Herbert Irving Comprehensive Cancer Center, New York, New York, United States
- Duke University Health System (DUHS), Durham, North Carolina, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03731260 on ClinicalTrials.govOther trials for Indolent systemic mastocytosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07255638A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in GermanyBlueprint Medicines Corporation
- ACTIVE NOT RECRUITINGPHASE2NCT05186753(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic MastocytosisCogent Biosciences, Inc.
- RECRUITINGPHASE2, PHASE3NCT04910685(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic MastocytosisBlueprint Medicines Corporation
- RECRUITINGPHASE2NCT04655118Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic MastocytosisTelios Pharma, Inc.